腮腺转移性皮肤鳞状细胞癌:区域复发率与生存分析
澳大利亚三级癌症中心回顾性分析2003–2014年78例腮腺转移性皮肤鳞状细胞癌患者,65例行浅叶腮腺切除术,82%接受辅助放疗。辅助放疗与5年生存率提高(50% vs 20%)及2年区域控制率提高(89% vs 40%)相关,放疗组腮腺床复发率3.7% vs 未放疗组27%。结论支持手术联合辅助放疗为标准治疗,常规选择性深叶切除可能并非必需。
要点
- 辅助放疗与5年生存率提高相关(50% vs 20%)
- 辅助放疗与2年区域控制率提高相关(89% vs 40%)
- 放疗组腮腺床复发率3.7%,未放疗组27%
核心结论
- 手术联合辅助放疗支持作为腮腺转移性cSCC的标准治疗。
- 该方案下腮腺床复发率低,提示常规选择性深叶切除可能并非必需。
研究设计与样本
- 回顾性队列研究,纳入2003–2014年澳大利亚三级癌症中心78例腮腺转移性cSCC患者。
- 患者接受治愈性腮腺切除术(浅叶或全叶),伴或不伴颈淋巴结清扫。
主要发现
- 中位随访6.5年。
- 选择性颈淋巴结清扫中6例(24%)发现颈淋巴结转移。
- 耳前、面、颈外静脉及枕部淋巴结受累者占36.9%。
关键数值与推荐
- 辅助放疗组5年生存率50%(95% CI 36%-69%),未放疗组20%(95% CI 6%-70%)。
- 辅助放疗组2年区域控制率89%(95% CI 67%-100%),未放疗组40%(95% CI 14%-100%)。
- 辅助放疗组同侧腮腺床复发率3.7%,未放疗组27%。
临床怎么用
- 对腮腺转移性cSCC患者,推荐手术联合辅助放疗。
- 基于低腮腺床复发率,可考虑不常规行选择性深叶切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives Extent of parotidectomy and neck dissection for metastatic cutaneous squamous cell carcinoma (cSCC) to the parotid is debated. We describe our experience, analyzing outcomes (overall survival and regional recurrence) associated with surgical extent and adjuvant treatment. Study Design A retrospective cohort study of parotidectomy with or without neck dissection for metastatic cSCC. Setting A tertiary referral cancer center in Australia. Subjects and Methods The study group consisted of patients with metastatic cSCC involving the parotid gland who underwent a curative-intent parotidectomy (superficial or total), with or without neck dissection, between 2003 and 2014. Demographic and clinical data, treatment modalities, and outcome parameters were collected from the electronic institutional database. Results Of 78 patients, 65 underwent superficial parotidectomy. Median follow-up was 6.5 years. Sixty-four patients (82%) patients received adjuvant radiotherapy. Cervical lymph nodes were involved in 6 (24%) elective neck dissections. Involved preauricular, facial, external jugular, and occipital nodes occurred in 36.9%. Adjuvant radiotherapy was associated with improved 5-year survival-50% (95% CI, 36%-69%) versus 20% (95% CI, 6%-70%)-and improved 2-year regional control: 89% (95% CI, 67%-100%) versus 40% (95% CI, 14%-100%). The ipsilateral parotid bed recurrence rate was 3.7% for those who received adjuvant radiotherapy and 27% for those who did not receive radiotherapy. Conclusion This study supports surgery plus adjuvant radiotherapy as a standard of care for metastatic cSCC. The low incidence of parotid bed recurrence with this approach suggests that routine elective deep lobe resection may not be required.
引用
- Hirshoren N, Ruskin O, McDowell LJ, et al. Management of Parotid Metastatic Cutaneous Squamous Cell Carcinoma: Regional Recurrence Rates and Survival. Otolaryngol Head Neck Surg. 2018. PMID: 29533706. doi:10.1177/0194599818764348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。